US Patent Issued to RADIONETICS ONCOLOGY on July 21 for "Neuropeptide Y1 receptor (NPY1R) targeted therapeutics and uses thereof" (California Inventors)

ALEXANDRIA, Va., July 21 -- United States Patent no. 12,685,789, issued on July 21, was assigned to RADIONETICS ONCOLOGY INC. (San Diego).

"Neuropeptide Y1 receptor (NPY1R) targeted therapeutics and uses thereof" was invented by Yifeng Xiong (San Diego), Junjie Liu (San Diego) and Yunfei Zhu (San Diego).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described herein are radiotherapeutics that target tumor cells expressing the neuropeptide Y1 receptor (NPY1R) and their use in the treatment and/or diagnosis of cancer."

The patent was filed on Dec. 26, 2024, under Application No. 19/002,144.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?S...